SCYNEXIS Says On March 15, 2026 Co Received FDA Orphan Drug Designation For Brexafemme (Triterpenoid Antifungal) For Treatment Of Invasive Candidiasis

Benzinga Newsdesk www.benzinga.com Neutral 92.0%

Neg 0% Neu 92% Pos 0%

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1123525

Comments

No comments yet. Be the first!